Feedback / Questions
LBL-007 - BeiGene
BGB-15025 - BeiGene
BGB-A445 - BeiGene
Tevimbra (tislelizumab) - BeiGene
https://www.businesswire.com/news/home/20240508878785/en/BeiGene-Reports-First-Quarter-2024-Financial-Results-and-Business-Updates
May 8, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next